Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Yesterday, May 15, 2014, 142 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $600.00 to $30,330,507.50.

Highlighted Stocks Traded by Insiders:

InterMune (ITMN) - FREE Research Report

Hodgman John, who is EVP, Finance & CFO at InterMune, sold 941 shares at $35.19 on May 15, 2014. Following this transaction, the EVP, Finance & CFO owned 21,713 shares meaning that the stake was reduced by 4.15% with the 941-share transaction.

The shares most recently traded at $33.28, down $1.91, or 5.74% since the insider transaction. Historical insider transactions for InterMune go as follows:

  • 4-Week # shares sold: 9,950
  • 12-Week # shares sold: 156,648
  • 24-Week # shares sold: 296,648

The average volume for InterMune has been 3.6 million shares per day over the past 30 days. InterMune has a market cap of $3.5 billion and is part of the health care sector and drugs industry. Shares are up 137.68% year-to-date as of the close of trading on Thursday.

InterMune, Inc., a biotechnology company, focuses on the research, development, and commercialization of therapies for pulmonology and orphan fibrotic diseases in North America and Europe. Currently, there are 8 analysts who rate InterMune a buy, 1 analyst rates it a sell, and 3 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on ITMN - FREE

TheStreet Quant Ratings

rates InterMune as a

sell

. Among the areas we feel are negative, one of the most important has been generally deteriorating net income. Get the full

InterMune Ratings Report

from

TheStreet Quant Ratings

now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Walter Investment Management (WAC) - FREE Research Report

Anderson Keith A, who is EVP and COO at Walter Investment Management, sold 10,000 shares at $30.00 on May 15, 2014. Following this transaction, the EVP and COO owned 36,611 shares meaning that the stake was reduced by 21.45% with the 10,000-share transaction.

The shares most recently traded at $27.40, down $2.60, or 9.49% since the insider transaction. Historical insider transactions for Walter Investment Management go as follows:

  • 4-Week # shares bought: 2,500
  • 4-Week # shares sold: 8,765
  • 12-Week # shares bought: 2,500
  • 12-Week # shares sold: 8,765
  • 24-Week # shares bought: 3,500
  • 24-Week # shares sold: 10,665

The average volume for Walter Investment Management has been 1.1 million shares per day over the past 30 days. Walter Investment Management has a market cap of $1.1 billion and is part of the financial sector and real estate industry. Shares are down 18.52% year-to-date as of the close of trading on Thursday.

Walter Investment Management Corp., together with its subsidiaries, provides business services to the residential mortgage industry in the United States. The company has a P/E ratio of 4.6. Currently, there are 5 analysts who rate Walter Investment Management a buy, no analysts rate it a sell, and 3 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on WAC - FREE

TheStreet Quant Ratings

rates Walter Investment Management as a

sell

. The company's weaknesses can be seen in multiple areas, such as its poor profit margins and generally disappointing historical performance in the stock itself. Get the full

Walter Investment Management Ratings Report

from

TheStreet Quant Ratings

now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

XOMA (XOMA) - FREE Research Report

Rubin Paul D, who is Sr. VP Clinical Dev. & CMO at XOMA, sold 10,000 shares at $3.84 on May 15, 2014. Following this transaction, the Sr. VP Clinical Dev. & CMO owned 80,719 shares meaning that the stake was reduced by 11.02% with the 10,000-share transaction.

The shares most recently traded at $3.54, down $0.30, or 8.49% since the insider transaction. Historical insider transactions for XOMA go as follows:

  • 4-Week # shares sold: 2,671
  • 12-Week # shares sold: 2,671
  • 24-Week # shares sold: 2,977

The average volume for XOMA has been 2.7 million shares per day over the past 30 days. XOMA has a market cap of $396.6 million and is part of the health care sector and drugs industry. Shares are down 46.66% year-to-date as of the close of trading on Thursday.

XOMA Corporation discovers and develops antibody-based therapeutics in the United States, Europe, and the Asia Pacific. Currently, there are 6 analysts who rate XOMA a buy, no analysts rate it a sell, and none rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on XOMA - FREE

TheStreet Quant Ratings

rates XOMA as a

sell

. The company's weaknesses can be seen in multiple areas, such as its deteriorating net income and feeble growth in its earnings per share. Get the full

XOMA Ratings Report

from

TheStreet Quant Ratings

now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

null